MAP2K7 and acute lymphoblastic leukemia: Trametinib, a selective MEK inhibitor, has demonstrated preclinical efficacy against RAS-mutant, MLL-rearranged ALL within specific microenvironmental niches, where it effectively reduces ERK phosphorylation in vivo [36, 37].